Melanoma Dispatch
2.6K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

PV-10 Produced Complete Response in 50% of Advanced Melanoma Patients

"Half of patients with locally advanced cutaneous melanoma who had all their lesions injected with the investigational agent PV-10 achieved a complete response in a phase 2 study, according to a presentation at the 50th American Society of Clinical Oncology meeting, held in Chicago, IL, May 30th to June 2nd."

Editor's note: PV-10 is a new drug that can be injected directly into a cutaneous melanoma tumor. In a recent clinical trial testing the drug on volunteers, half of all patients who had all of their tumors injected experienced complete disappearance of their tumors.

Cancer Commons's insight:

Medical News Today  |  Jun 10, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Will PV-10 Injections Shrink Melanomas in People, Too?

Will PV-10 Injections Shrink Melanomas in People, Too? | Melanoma Dispatch | Scoop.it

A new phase I clinical trial is underway to see if an experimental melanoma treatment works as well in people as it does in mice. The treatment entails injecting tumors with PV-10. A previous study in mice showed that just one PV-10 injection was enough to  shrink melanomas. In addition, very early trials suggested that PV-10 boosts the immune system and the mouse study suggested that this treatment has fewer side effects than current immunotherapies. The new trial will assess whether PV-10 shrinks melanomas and keeps them from spreading in people, as well as whether PV-10 actually boosts the immune system. This trial is currently accepting participants.

Cancer Commons's insight:

ASCO Post│Aug 28, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting

"Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA. These clinical and pathologic changes were accompanied by increases in important immune cell populations detected in the patients' peripheral blood."


Editor's note: This story is about a new treatment called PV-10 that is injected directly into melanoma tumors. A clinical trial to test the drug in people with melanoma has shown promising results. The manufacturers of the drug have submitted an application for "breakthrough therapy" designation from the U.S. Food and Drug Administration (FDA) to expedite the FDA-approval process and rapidly make the drug available to many more melanoma patients in the U.S.

Cancer Commons's insight:

Provectus Biopharmaceuticals  |  Apr 7, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Clinical Trial to Determine if PV-10 Boosts Immune System

The experimental drug PV-10, which is injected directly into melanoma tumors, may work partly by boosting the immune system. To find out, researchers are launching a clinical trial to see if patients treated with PV-10 have immune biomarkers in their tumors and blood. The study will enroll up to 15 patients.

Cancer Commons's insight:

News-Medical.Net | Jan 9, 2013

more...
No comment yet.